Atalay, S.; van den Reek, J. M.; Otero, M. E.; Njoo, M. D.; Mommers, J. M.; Ossenkoppele, P. M.; Koetsier, M. I.; Berends, M. M.; van de Kerkhof, P. C.; Groenewoud, H. M. Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared With Standard Psoriasis Care: A Cost-Utility Analysis of the CONDOR Study. Acta Derm Venereol 2020, 100, 1-7.